Settlement disappoints | FDA approvals encourage
Updates covered here include news of a cash settlement for an unloved legal services business, a significant forward sale for an equally unloved developer and approvals for two more highly rated companies supporting the health sector. Read on here for this and other news.
Diaceutics: significant contract award Diaceutics (AIM: DXRX), a technology and solutions provider to the pharmaceutical industry, announced a three-year enterprise contract with a US-based top 10 global pharmaceutical company. The contract will initially deliver US$10.1m of revenue over a three-year period, however, there are additional options which, if exercised, would significantly increase the scope and value over this period. Revenue is expected to be recognised on a monthly basis, spread broadly evenly over the course of the contract, starting immediately. The company generated revenues of £19.5m in 2022 so this is a significant contract win. Diaceutics will deliver a wide…